All News

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a voluntary pause.

Proceeding with hematopoietic stem cell transplantation (HSCT) is more cost-effective than delaying the procedure in patients with intermediate-risk acute myeloid leukemia (AML).

A cumulative review offers strong evidence that acalabrutinib has a low incidence of cardiac failure in both clinical trial and real-world settings.

TACE combined with SBRT enhanced survival rates in patients with large hepatocellular carcinoma tumors, offering promising treatment insights.

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates.

Larazotide, a therapy known to treat celiac disease, shows promise as a safe treatment for multisystem inflammatory syndrome in children linked to COVID-19, enhancing recovery and symptom resolution.

The Commonwealth Fund’s updated July 2025 brief on maternal mortality highlights how systemic disparities, Medicaid coverage gaps, and behavioral health challenges continue to drive poor maternal and infant outcomes across the United States.

Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.

Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.

Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.

The decline in ovarian cancer mortality rates after 2003 can be attributed to advances in treatment, precision medicine, improved preventive strategies, and a reduced disease incidence, according to Muhammad Faizan, MBBS.

In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and adolescents with moderate to severe plaque psoriasis.

With inflammation being the cause of dry eye in many cases, future treatment will likely target this aspect of dry eye.

Discover the latest insights on pediatric-onset multiple sclerosis, emphasizing early intervention and high-efficacy therapies for improved outcomes in children.

Individuals with mental illness in America continue to face socioeconomic barriers when it comes to accessing necessary care and treatment.

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, and greater competition in the B-cell maturation antigen (BCMA) bispecific antibody space.

When updated food allergy prevention guidelines were directly provided to families, they led to earlier allergen introduction in infants and significantly reduced the prevalence of IgE-mediated peanut, egg, and cow's milk allergies.

Factors such as age, smoking status, and body mass index can help clinicians predict a patient’s risk of 30-day mortality.

US ovarian cancer mortality declined from 1999 to 2020, but significant disparities remain among older women, non-Hispanic White women, and those living in rural areas, as well as in the Northeastern and Midwestern regions, according to Muhammad Faizan, MBBS.

Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the association is necessarily a causal one.

Nurses enhance chronic kidney disease (CKD) care by implementing a palliative CKD care framework, addressing barriers, and promoting patient-centered supportive strategies globally.

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community settings, according to Sundar Jagannath, MBBS.

Quality of life in people living with HIV was lower in those who had weight gain from adherence to antiretroviral therapy.

The study aims to build an accurate, interpretable model for stage III colorectal cancer prognosis.

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.